First-In-Human, Multicenter, Dose-Escalation, Phase I Study Of The Investigational Drug Tak-733, An Oral Mek Inhibitor, In Patients (Pts) With Advanced Nonhematologic Malignancies And Melanoma.
JOURNAL OF CLINICAL ONCOLOGY（2011）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要